LOS ANGELES, April 15 (Xinhua) -- The U.S. Food and Drug Administration (FDA) has warned consumers not to use counterfeit Ozempic (semaglutide) found in the U.S. drug supply chain.
The FDA said on Monday it was notified by Novo Nordisk, the drugmaker of Ozempic, that several hundred units of counterfeit Ozempic injection 1mg were in the U.S. drug supply chain. The FDA seized the identified counterfeit products on April 9.
